PartnershipCollaboration to develop mRNA vaccine agai...CEPI fights the betacoronaviruses by funding Ethris GmbH and DIOSynVax Ltd and their joint effort to advance their work on an mRNA vaccine. more ➔
immunoncologyFirst allogeneic cancer immunotherapy hits...Atara Biotherapeutics Inc. and Pierre Fabre SA announced the approval of Tabelecleucel, a therapy for a rare and potentially fatal malignancy. more ➔
financingNumares AG cashes in €20m from EIBThe European Investment Bank (EIB) is going to support the AI-platform of NMR/metabolomics diagnostics company Numares AG to improve disease prediction. more ➔
INDUSTRIA BIOTEC 2023 with a broader persp..."Solutions for an endangered planet" is what industrial biotechnology seeks and offers. Technical innovations based on nature’s toolbox are intended to help "biologise" industry – … more ➔
AMR€72M from Novo´s REPAIR Impact Fund for...MinervaX inks €72m financing deal with Novo Holdings REPAIR Impact Fund to develop a vaccine against Group B Streptococcus. more ➔
A ray of hope in leukaemiaA child with recurrent T-cell leukaemia was given base-edited T-cells in a world-first application of a base-edited cell therapy. more ➔
Amgen wins race of top `22 deals with $26b...According to Bloomberg, the US biotechnology giant Amgen plans to buy Horizon Therapeutics at a valuation of about $26bn. Overall, the deal corresponds to an enterprise value including debt of $28.3bn. … more ➔
Step Pharma presents promising cancer trea...Step Pharma intruduces promising data on the potential of a selective cancer treatment by inhibition of CTPS1 with their inhibitor STP938. more ➔
Partnering revitalized at the BioFit2022 &...The partnering event BioFit2022 took place in Strasbourg, France on November 29th and 30th as well as online on December 7th and 8th. It reflected on challenging times in the pandemic, survivors … more ➔
M&AEuropean Commission calls for reversal of... The European Commission has now recommended concrete steps that, while not yet final, would require Illumina to "swiftly" reverse its controversial $7.1bn acquisition of Grail. more ➔
